Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 46 out of 100. Brain tissue and pathology

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

Alzheimer disease (AD) is a progressive neurodegenerative disease marked by the accumulation of extracellular β-amyloid (Aβ) plaques and intracellular neurofibrillary tangles containing tau protein. Given the relentless deterioration in AD, strategies to slow its progression often focus on inhibiting Aβ production or aggregation. However, numerous clinical trials targeting Aβ in later disease stages have shown limited success in reversing cognitive decline, potentially due to intervening too late in the disease course. Emerging evidence suggests that addressing Aβ pathology during the earliest phases of AD, before the occurrence of neuronal damage, may be beneficial for preserving cognitive function. Thus, therapeutic approaches aimed at reducing Aβ levels, such as anti-Aβ antibodies, are likely to yield greater benefits when implemented early in the disease trajectory. Such evidence underscores the rationale for prioritizing early-stage interventions in AD drug development. However, disrupting the physiological role of Aβ, which plays a role in normal brain function, might inadvertently worsen clinical outcomes, highlighting the need for nuanced therapeutic strategies. Therefore, this review aims to explore the dual aspects of Aβ biology: its natural role in the brain and the potential of anti-Aβ immunotherapy, particularly targeting amyloid plaques, as a promising avenue for modifying AD progression when timed appropriately. SIGNIFICANCE STATEMENT: This review highlights that β-amyloid (Aβ) has a dual role in both supporting synaptic plasticity and memory via nicotinic receptor activation and driving Alzheimer disease neuropathology, emphasizing that early-stage Aβ-targeted immunotherapy may prevent cognitive decline while preserving the neuroprotective functions of Aβ, thereby refining therapeutic strategies and advancing understanding of the complex role of Aβ in neural health and disease.

What this study adds

Evidence grade: Low

This review notes that many clinical trials targeting amyloid-beta in later disease stages showed limited success in reversing cognitive decline, possibly because treatment started too late. It suggests anti-amyloid-beta approaches may work better when given early, before neuronal damage, while cautioning that amyloid-beta also has normal brain functions that could be disrupted.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Almohmadi, N. H., Al-Kuraishy, H. M., Albuhadily, A. K., Al-Gareeb, A. I., Abdelaziz, A. M., Alexiou, A. T., et al. (2025). Alzheimer disease: Amyloid peptide controversies and challenges of anti-Aβ immunotherapy. Journal of Pharmacology and Experimental Therapeutics. https://doi.org/10.1016/j.jpet.2025.103639

Vancouver

Almohmadi NH, Al-Kuraishy HM, Albuhadily AK, Al-Gareeb AI, Abdelaziz AM, Alexiou AT, et al. Alzheimer disease: Amyloid peptide controversies and challenges of anti-Aβ immunotherapy. Journal of Pharmacology and Experimental Therapeutics. 2025. doi:10.1016/j.jpet.2025.103639. PMID: 40674941.

BibTeX

@article{almohmadi2025-40674941,
  author  = {Almohmadi, Najlaa H. and Al-Kuraishy, Hayder Mutter and Albuhadily, Ali K. and Al-Gareeb, Ali Ismail and Abdelaziz, Ahmed M and Alexiou, Athanasios T. and Papadakis, Marios and Batiha, Gaber El‐Saber},
  title   = {{Alzheimer disease: Amyloid peptide controversies and challenges of anti-Aβ immunotherapy}},
  journal = {Journal of Pharmacology and Experimental Therapeutics},
  year    = {2025},
  doi     = {10.1016/j.jpet.2025.103639},
  pmid    = {40674941},
  url     = {https://doi.org/10.1016/j.jpet.2025.103639}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 8 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.

Key findings

Why it matters

This review notes that many clinical trials targeting amyloid-beta in later disease stages showed limited success in reversing cognitive decline, possibly because treatment started too late. It suggests anti-amyloid-beta approaches may work better when given early, before neuronal damage, while cautioning that amyloid-beta also has normal brain functions that could be disrupted.

Study details

How this study scored 46/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 3 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 4 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 0 of 3; Randomized / blinded 0 of 2; Times cited 3 of 7; Citations per year 3 of 5; Impact for its field and year 4 of 6; Cited by studies here 0 of 6; Still being cited 2 of 4; Senior author's track record 3 of 4; Institution's track record 0 of 3; Multicenter collaboration 2 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. Total 46 of 100.46 of 100 points earned54 not earned

Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Journal of Pharmacology and Experimental Therapeutics)
Journal's citation record 3 / 4 Journal of Pharmacology and Experimental Therapeutics: journal h-index 327 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 4 / 5 2025 — within 3 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 3 / 7 Cited 25 times (OpenAlex, 2026-10-10)
Citations per year 3 / 5 8.3 citations a year over 3 year(s) since 2025
Impact for its field and year 4 / 6 Cited 13.7× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 2 / 4 Cited 25 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 3 / 4 Last-listed author Gaber El‐Saber Batiha: h-index 72 (OpenAlex, whole career)
Institution's track record 0 / 3 Witten/Herdecke University: institution h-index 335 (OpenAlex)
Multicenter collaboration 2 / 3 OpenAlex lists 7 institution(s) in 5 countries
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 40674941)
Free to read 2 / 2 Free to read
Total 46 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 21.

Related studies in Brain tissue and pathology from nearby years

Also in Brain tissue and pathology

124 studies in the library are filed under Brain tissue and pathology with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Brain tissue and pathology hub.

Similar studies

More on Brain tissue and pathology

See all studies in Brain tissue and pathology →